

References

L-205

1. Chou R, Gore JL, Buckley D, et al. Urinary biomarkers for diagnosis of bladder cancer: a systematic review and meta-analysis. *Ann Intern Med.* 2015 Dec 15;163(12):922-31.
2. What is Cxbladder. Pacific Edge Limited: Cxbladder website. Available at: www.cxbladder.com/us/.
3. National Comprehensive Cancer Network 2016 Clinical Practice Guidelines in Oncology: Bladder Cancer. V.1.2017.
4. Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.* 2010;153:461-468.
5. Breen V, Kasabov N, Kamat AM, et al. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. *BMC Med Res Methodol.* 2015 May 12;15:45.
6. Kavalieris L, O'Sullivan PJ, Suttie JM, et al. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma. *BMC Urol.* 2015 Mar 27;15:23.
7. O'Sullivan P, Sharples K, Dalphin M, et al. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria. *J Urol.* 2012 Sep;188(3):741-7.
8. Holyoake A, O'Sullivan P, Pollock R, et al. Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. *Clin Cancer Res.* 2008 Feb 1;14(3):742-9.
9. Pacific Edge Limited. A Clinical, Non-intervention Study of the Cxbladder Urine Test for the Detection of Recurrent Urothelial Carcinoma (UC). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 – [cited 2017 Jan 16].